Cargando…

Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA

To report a multi-institutional case series of patients with advanced microsatellite instability high (MSI-H) prostate adenocarcinoma identified with clinical cell-free DNA (cfDNA) next-generation sequencing (NGS) testing and treated with immune checkpoint inhibitors. Retrospective analysis of patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barata, Pedro, Agarwal, Neeraj, Nussenzveig, Roberto, Gerendash, Benjamin, Jaeger, Ellen, Hatton, Whitley, Ledet, Elisa, Lewis, Brian, Layton, Jodi, Babiker, Hani, Bryce, Alan, Garje, Rohan, Stein, Cy, Kiedrowski, Lesli, Saylor, Philip, Sartor, Oliver
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7422632/ https://www.ncbi.nlm.nih.gov/pubmed/32788235 http://dx.doi.org/10.1136/jitc-2020-001065

Ejemplares similares

Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer
por: Chakrabarti, Sakti, et al.
Publicado: (2022)

IMMU-26. DISEASE CONTROL IN A PEDIATRIC PATIENT WITH NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM) AND SOMATIC HIGH MICROSATELLITE INSTABILITY (MSI-H) WITH PD-1 INHIBITOR NIVOLUMAB (NIVO) ONLY AND NO FOCAL RADIOTHERAPY (RT)
por: Larkin, Trisha, et al.
Publicado: (2020)

Black Patients with Metastatic Castrate-Resistant Prostate Cancer Have a Shorter Time Interval Between PSA and Clinical Progression on Novel Hormonal Therapies plus Avelumab
por: Hawkins, Charlotte (Manogue), et al.
Publicado: (2022)

Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers
por: Fucà, Giovanni, et al.
Publicado: (2022)

T057: Circulating tumor DNA in classical Hodgkin lymphoma patients treated with pembrolizumab and chemotherapy: dynamic response assessment and correlation with baseline total metabolic tumor volume
por: Lynch, Ryan C., et al.
Publicado: (2022)

P061: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
por: Borchmann, Peter, et al.
Publicado: (2022)

T058: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD-1 Treatment
por: Timmerman, John, et al.
Publicado: (2022)

Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer
por: Wang, Zhenghang, et al.
Publicado: (2022)

Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer
por: Nasca, Vincenzo, et al.
Publicado: (2023)

Evaluation of the genomic alterations in the androgen receptor gene during treatment with high-dose testosterone for metastatic castrate-resistant prostate cancer
por: Moses, Marcus, et al.
Publicado: (2020)

Safety and efficacy of letetresgene autoleucel alone or with pembrolizumab for relapsed/refractory multiple myeloma
por: Nishihori, Taiga, et al.
Publicado: (2022)

Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort
por: Barata, Pedro, et al.
Publicado: (2020)

Response to Nivolumab and Ipilimumab in Microsatellite Instability-High (MSI-H) Cervical Carcinoma with Acquired Resistance to Pembrolizumab: A Case Report and Literature Review
por: Gim, Gahyun, et al.
Publicado: (2022)

Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer
por: Chun, Brie, et al.
Publicado: (2022)

Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumab
por: Watson, Geoffrey Alan, et al.
Publicado: (2022)

Evaluation of tumor antigen-specific antibody responses in patients with metastatic triple negative breast cancer treated with cyclophosphamide and pembrolizumab
por: Routh, Eric D, et al.
Publicado: (2023)

Plasma-based microsatellite instability detection strategy to guide immune checkpoint blockade treatment
por: Wang, Zhenghang, et al.
Publicado: (2020)

Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors
por: Cristescu, Razvan, et al.
Publicado: (2022)

DeltaMSI: artificial intelligence-based modeling of microsatellite instability scoring on next-generation sequencing data
por: Swaerts, Koen, et al.
Publicado: (2023)

Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer
por: Ledet, Elisa M., et al.
Publicado: (2021)

Impact of immune-related adverse events on the therapeutic efficacy of pembrolizumab in urothelial carcinoma: a multicenter retrospective study using time-dependent analysis
por: Kawai, Taketo, et al.
Publicado: (2022)

Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA
por: Swami, Umang, et al.
Publicado: (2022)

Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma
por: Haddad, Robert I, et al.
Publicado: (2022)

Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability–High Locally Advanced Rectal Cancer
por: Bando, Hideaki, et al.
Publicado: (2022)

Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)
por: Ricciuti, Biagio, et al.
Publicado: (2021)

Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target
por: Wang, Haizhou, et al.
Publicado: (2022)

PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis
por: Lo Russo, Giuseppe, et al.
Publicado: (2023)

Detection of microsatellite instability with Idylla MSI assay in colorectal and endometrial cancer
por: Ukkola, Iiris, et al.
Publicado: (2021)

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study
por: Oaknin, Ana, et al.
Publicado: (2022)

Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer
por: Egelston, Colt, et al.
Publicado: (2021)

Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia
por: Goswami, Meghali, et al.
Publicado: (2022)

Use of pembrolizumab in MSI-high uterine leiomyosarcoma; a case report and review of the literature
por: Wang, Yannan J., et al.
Publicado: (2021)

Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer
por: Alessi, Joao V, et al.
Publicado: (2021)

Phase 2 study of pembrolizumab in patients with advanced rare cancers
por: Naing, Aung, et al.
Publicado: (2020)

Clinical Activity of Combined Telomerase Vaccination and Pembrolizumab in Advanced Melanoma: Results from a Phase I Trial
por: Ellingsen, Espen B., et al.
Publicado: (2023)

Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma
por: Bedrose, Sara, et al.
Publicado: (2020)

Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin’s lymphoma
por: Lurain, Kathryn, et al.
Publicado: (2021)

Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers
por: Colen, Rivka R, et al.
Publicado: (2021)

Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors
por: Hurkmans, Daan P., et al.
Publicado: (2021)

IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation
por: Rozeman, Elisa A, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jj4ca6sv75jn4oib2fc720lep2